Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Multiple medication use may increase severity of erectile dysfunction

The use of multiple medications is associated with increased severity of erectile dysfunction, according to a Kaiser Permanente study published online in the British Journal of Urology International.

15 Nov 2011

Risk of heart failure appears to be higher among low-income seniors

The risk of heart failure appears to be higher among low-income seniors — even those with a college education — according to research from the University of Alabama at Birmingham presented during the 2011 American Heart Association Scientific Sessions.

15 Nov 2011

Smoke-free workplace laws help reduce heart attacks and save lives

Mayo Clinic researchers have amassed additional evidence that secondhand smoke kills and smoke-free workplace laws save lives.

14 Nov 2011

BSP completes HyperQ technology clinical research study on CAD

BSP Biological Signal Processing Ltd. (BSP), which develops and manufactures products for the non-invasive, accurate diagnosis of Coronary Artery Disease (CAD), recently announced the successful completion of a comprehensive clinical research study evaluating the performance of the company's HyperQ technology in diagnosing CAD.

14 Nov 2011

UCLA School of Nursing faculty members to present at AHA 2011

A failing heart's effect on the short-term memory. The impact of telephone interventions on behaviors in Latinos. Depression and heart disease. Risk factors contributing to premature coronary atherosclerosis in premenopausal women. These are just a few of the research findings that will be presented by faculty members of the UCLA School of Nursing at the American Heart Association's Scientific Sessions, being held November 12 - 16 in Orlando, FL.

14 Nov 2011

Alcohol consumption may decrease risk of death from coronary artery disease

In a prospective, observational study of approximately 150,000 Norwegians, the investigators found that alcohol consumption was associated with a large decrease in the risk of death from coronary artery disease.

11 Nov 2011

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) have found.

10 Nov 2011

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.

9 Nov 2011

Cordis receives FDA 510(k) clearance for EMPIRA Balloon Catheters

Cordis Corporation today announced EMPIRA and EMPIRA NC RX PTCA Dilatation Catheters have received 510(k) regulatory clearance for the treatment of coronary artery disease.

8 Nov 2011

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).

7 Nov 2011

InfraReDx TVC Imaging System to be exhibited at TCT 2011

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System for the true vessel characterization of coronary artery disease will be highlighted during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2011).

7 Nov 2011

InfraReDx launches enhanced version of LipiScan IVUS Coronary Imaging System

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced the launch of its TVC Imaging System, an enhanced version of the LipiScan IVUS Coronary Imaging System.

7 Nov 2011

Dual imaging approach could improve diagnosis, treatment of coronary artery disease

A new device that combines two microimaging technologies can reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could indicate the risk of heart attacks or the formation of clots in arterial stents.

7 Nov 2011

Anti-TNFs, methotrexate may reduce risk of cardiovascular disease in people with RA

Taking methotrexate or anti-TNFs is associated with a reduction in risk of cardiovascular disease in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

2 Nov 2011

New drug could combat cardiovascular disease

A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

29 Oct 2011

Apnex Medical's HGNS System receives CE Mark approval for treatment of OSA

Apnex Medical, Inc., has received CE Mark approval for its Hypoglossal Nerve Stimulation System for use by people who suffer from obstructive sleep apnea.

28 Oct 2011

Clinical and genetic risk factors associated with early stent thrombosis

Patients with certain genes or specific factors related to use of the anti-clotting drug clopidogrel are more likely to experience a blood clot within a coronary stent shortly after placement, according to a study in the October 26 issue of JAMA.

27 Oct 2011